EXPERT OPINION

Explore opinions from healthcare professionals who are passionate about optimising management of patients with type 2 diabetes.

Improving Diabetes Steering Committee – Appropriate use of SGLT2i’s

The Improving Diabetes Steering Committee has developed a consensus document to provide UK prescribers with balanced and accurate information about diabetes medicines, particularly around the appropriate use of SGLT2 inhibitors.

View the consensus document

IMPROVING DIABETES STEERING COMMITTEE – SGLT2 INHIBITORS: BENEFITS BEYOND HBA1C – TRANSLATING EVIDENCE INTO PRACTICE

Cardiovascular disease (CVD), including heart failure (HF), is a leading causes of morbidity and mortality in people with type 2 diabetes (T2D). This paper examines the role of SGLT2i therapy for people with T2D who are at risk of, or who have, CVD.

View the consensus document